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1 Department of Drug Discovery and Development Department, St. Catharines, ON, Canada, 2 Pathology and Laboratory
Medicine, Western University and London Health Sciences Centre, London, ON, Canada
The emergence of extended- spectrum β-lactamase (ESBL) is the underlying cause
of growing antibiotic resistance among Gram-negative bacteria to β-lactam antibiotics.
We recently reported the discovery of honey glycoproteins (glps) that exhibited a rapid,
concentration-dependent antibacterial activity against both Gram-positive Bacillus
subtilis and Gram-negative Escherichia coli that resembled action of cell wall-active
β-lactam drugs. Glps showed sequence identity with the Major Royal Jelly Protein
1 (MRJP1) precursor that harbors three antimicrobial peptides: Jelleins 1, 2, and 4.
Here, we used semi-quantitative radial diffusion assay and broth microdilution assay
to evaluate susceptibility of a number of multi-drug resistant (MDR) clinical isolates to
the MRJP1-contaning honey glycoproteins. The MDR bacterial strains comprised three
methicillin-resistant Staphylococcus aureus (MRSA), four Pseudomonas aeruginosa,
two Klebsiella pneumoniae, two vancomycin-resistant Enterococci (VRE), and five ESBL
identified as one Proteus mirabilis, three E. coli, and one E. coli NDM. Their resistance
to different classes of antibiotics was confirmed using automated system Vitek 2. MDR
isolates differed in their susceptibility to glps with MIC90 values ranging from 4.8 μg/ml
against B. subtilis to 14.4 μg/ml against ESBL K. pneumoniae, Klebsiella spp. ESBL
and E. coli and up to 33 μg/ml against highly resistant strains of P. aeruginosa. Glps
isolated from different honeys showed a similar ability to overcome bacterial resistance
to β-lactams suggesting that (a) their mode of action is distinct from other classes of
β-lactams and that (b) the common glps structure was the lead structure responsible
for the activity. The results of the current study together with our previous evidence of a
rapid bactericidal activity of glps demonstrate that glps possess suitable characteristics
to be considered a novel antibacterial drug candidate.
Keywords: multi-drug resistant, ESBL, clinical isolates, novel antibacterials, honey glycoproteins, Major Royal
Jelly Protein
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Introduction
The multi-drug resistant (MDR) bacterial pathogens
pose a signiﬁcant threat to control and treat bacterial
infections. Pathogens of particular concern include extended-
spectrum β-lactamase-producing (ESBL) Gram-negative
Enterobacteriaceae, including Escherichia coli, Klebsiella spp.,
Pseudomonas spp. and Proteus spp., the main causative agents
of nosocomial infections. ESBL arose from increased frequency
of mutations in β-lactamase gene in response to continuous
exposure of bacteria to new classes of β-lactams. Initially
chromosomally encoded TEM and SHV β-lactamases now
evolved to new varieties of ESBL enzymes that are predominantly
located on large plasmids, often together with genes conferring
resistance to other antibiotics such as aminoglycosides or
tetracyclines (Paterson and Bonomo, 2005). ESBLs are now
documented to be able to hydrolyze of oxyimino-β-lactams,
which include cefotaxime, ceftriaxone, ceftazidime, and
aztreonam, the main clinically available drugs used to treat severe
infections (Paterson and Yu, 1999; Bradford, 2001). Among
ESBL are carbapenamases, including serine-β-lactamases (KPC,
OXA) (Nordmann et al., 2009) and metallo-β-lactamases (MBLs)
such as New Delhi metallo-β-lactamase 1 (NDM-1; Bradford,
2001; Queenan and Bush, 2007). ESBL genes are consecutively
expressed and can be transfer to other bacterial species by
horizontal gene transfer via mobile elements such as plasmids
and transposons (Bradford, 2001; Warnes et al., 2012). These
mechanisms of transmission eﬀectively accelerate the spread of
MDR bacteria causing nosocomial outbreaks worldwide. Because
ESBL-producing strains present often MDR phenotypes, in order
to overcome their global resistance, new approaches in drug
discovery and designs are needed. These challenges led to re-new
interest in natural products as an untapped reservoir for drug
discovery (Koehn and Carter, 2005; Molinari, 2009; Hayashi
et al., 2013).
Our recent research into nature of antibacterial compounds
in honey led to isolation and sequence identiﬁcation of
glycoproteins as compounds chieﬂy responsible for honey
antibacterial activity (Brudzynski and Sjaarda, 2014, 2015).
MALDI TOF and electrospray quadrupole time of ﬂight mass
spectrometry (ESI-Q-TOF-MS/MS) analysis of glycoproteins
(glps) showed sequence identity with the Major Royal Jelly
Proteins 1 precursor (MRJP1).We have documented that the full-
length glps were able to (a) agglutinate bacterial cells due to a
several high-mannose structures attached to protein backbone
and (b) were able to induce phenotypic changes, (c) increase
bacterial membranes permeability and (d) to cause cell lysis. The
time-kill kinetics showed a rapid, >5-log10 reduction of viable
cells after addition of glps to bacterial cultures (Brudzynski and
Sjaarda, 2015).
TheMRJP1 has been implicated in several cellular functions in
honeybee (Schmitzova et al., 1998; Albert et al., 1999; Kupke et al.,
2012; Buttstedt et al., 2014) but it has never been linked before to
antibacterial eﬀects of honey. The MRJP1 glycoprotein harbors
three antimicrobial peptides, Jelleins (Fontana et al., 2004).
Synthetic Jelleins showed antibacterial activity in vitro against
Gram-positive and Gram-negative bacteria (Fontana et al., 2004).
The glps eﬀects on cell morphology, growth rate and
bactericidal activity resembled the action of β-lactam antibiotics
on cell envelope (Brudzynski and Sjaarda, 2014, 2015). The
full length glps and the β-lactams (penicillins, cephalosporins,
carbapenems), polymyxins and glycopeptides (vancomycin and
teicoplanin) share the ability to cause perturbation of the bacterial
cell wall and the membrane integrity. The above classes of drugs
structurally diﬀer between each other and aﬀect the membrane
integrity by diﬀerent mechanisms (Bush et al., 1995; Bush,
2012). The unexpected, novel function of MRJP1-containing
glycoproteins, its antibacterial activity, is our very recent ﬁnding
and the mode of action of glps has yet to be elucidated. To gain
some insight into this mechanism, we asked a simple question
whether general resistance of bacteria to β-lactams would impede
their sensitivity to glps.
The primary goal of this study was to determine whether
clinical isolates expressing mutli-MDR phenotypes are sensitive
to treatment with honey MRJP1-containing glycoproteins.
Materials and Methods
Isolation of Honey Glycoproteins
Glycoproteins were isolated from 25% aqueous honey solutions
using the agarose-immobilized Concavalin A spin columns
(Glycoprotein Isolation Kit, ConA, Thermo Scientiﬁc, Rockford,
IL, USA) according to the manufacturer’s manual. Two separate
spin columns were usually used to isolated glps from one honey
variety. The eluates were combined and lyophilized to dryness.
The isolation process was monitored by SDS-PAGE followed by
Coomassie blue staining.
Determination of Protein Concentration
Protein quantiﬁcation was performed by Bradford methods in
the microplate version, using the Bio-Rad Protein Assay (Bio-
Rad Laboratories Inc., Hercules, CA, USA) according to the
manufacturer instruction.
SDS-PAGE Electrophoresis (1D)
SDS-PAGE was performed according to the method described
by Laemmli (1970). Honey glycoproteins were analyzed by 7.5%
gel separation gel with attached 5% stacking gel. 30 μl of a
honey solution (50% v/v) or 15 μl of a fraction from ConA
chromatography were mixed with the sample buﬀer, denatured
at 100◦C for 5 min and loaded on a gel. The electrophoresis was
carried out in duplicate at a constant current of 100 Volts using
a Mini Protean III electrophoresis cell (Bio-Rad Laboratories,
Hercules, CA, USA). After electrophoresis, the gel was stained
with Brilliant Blue R-250 (Bio-Rad). The molecular weight of
the proteins was determined using molecular weight standards
(Fermentas Life Sciences, Fisher Scientiﬁc, Ottawa, ON, Canada).
Two-Dimensional Electrophoresis (2D)
Protein samples were rehydrated in a solution of 7 M
urea/2 M thiourea/4% CHAPS/0.5% carrier ampholytes/5 mM
tributylphosphine. Each sample was loaded onto a 17 cm pH 3-10
non-linear strip (BioRad) and allowed to passively rehydrate for
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18 h at 20◦C. IEF strips were focused on a BioRad PROTEAN IEF
cell at 10,000 Volts for 100,000 Volts/h.
Following the ﬁrst dimension the IEF strips were
equilibrated.in a solution of 50 mM Tris-HCl pH 8.8/ 6 M
urea/30% glycerol/2% SDS prior to loading the second
dimension. At this step the strips were also reduced and
alkylated using 1% DTT followed by 2.5% iodoacetamide. Once
equilibrated, the strips were loaded on a 10% homogeneous Tris-
Glycine gel and run overnight at 50 Volts and 12◦C.
Protein Digestion using the Micromass
MassPREP Robotic Protein Handling System
Gels were stained using non-destructive silver stain. Protein
plugs were excised from the gel using a coring device with
a 2 mm diameter. Gel plugs were de-stained in 15 mM
potassium ferricyanide/50 mM sodium thiosulfate and reduced
in 10 mM dithiothreitol in 100 mM ammonium bicarbonate
for 30 min. Samples were alkylated in 55 mM iodoacetamide in
100 mM ammonium bicarbonate for 20 min, washed in 100 mM
ammonium bicarbonate and dehydrated in 100% acetonitrile.
The samples were digested with 6 ng/uL trypsin (Promega
Sequencing Grade Modiﬁed Trypsin) in 50 mM ammonium
bicarbonate (25 uL) for 5 h at 37◦C. Peptides were extracted
from the gel plug with a solution of 30 uL 1% formic acid/2%
acetonitrile, and then with 24 uL of 50% acetonitrile follow the
ﬁrst extraction. Pooled extractions were evaporated down to a
volume of ∼20 uL using a ThermoSavant Speedvac concentrator
model SPD121P.
MALDI-TOF Mass Spectrometry
Spectra were acquired in positive-ion reﬂector mode and
analyzed on a Voyager DePro (Applied Biosystems Corporation)
using Data Explorer Version 5.1 software (Applied Biosystems
Corporation). The mass range scanned was 1000–3000 Da.
Raw spectra were processed under Data Explorer 5.1 software
(Applied Biosystems). Peptide peaks with a signal to noise
ratio of greater than 2:1 were selected for a database search.
Search parameters were set at trypsin with up to one missed
cleavage, ﬁxed carbamidomethyl modiﬁcation of cysteine and
variable oxidation of methionine. Database source was the
Mascot search engine using the NCBInr data base at 50 ppmmass
accuracy.
Antibacterial Assay of Glycoproteins by Agar
Well-Diffusion Method
The plates were prepared using Mueller-Hinton agar (MHA)
poured into layer of a 4 mm deep. The 100 μl of bacterial
inoculum (107 CFU/ml) was uniformly spread using a bent-
glass rod. Wells were performed with a sterile plastic bore of
3 mm diameter. Each well was ﬁlled with 8 μl of sample of
glycoproteins (40 μg/ml) prepared in three dilutions; undiluted,
2x and 4x diluted with sterile water. Each plate contained well-
ﬁlled with ampicillin (1 μg/10 μl or 5 μg/10 μl) as a positive
control and BSA (5 μg/10 μl), dissolved in the elution buﬀer
from Con A-chromatography, as a negative control. In addition,
the reference MHA plates were produced, inoculated with 100 μl
of either B. subtilis or E. coli (107 CFU/ml) that contained wells
ﬁlled with series of ampicillin concentrations ranging from 2.5
to 500 μg/ml. The agar plates were incubated for 24 h at 37◦C.
After incubation, the zone of inhibition of the bacterial growth
wasmeasured using a digital, electronic caliper (Flower Company
Inc., Newton, MA, USA). Tests were performed in duplicate.
Broth Microdilution Assay and Determination
of the MIC
The susceptibilities of clinical isolates and standard bacteria
(106 CFU/ml) to honey glycoproteins were analyzed using
broth microdilution assay in a 96 well-microtitre plate as
described previously (Brudzynski and Sjaarda, 2014). Each well-
contained 50 μl of inoculum and 8 μl of twofold serial
dilutions of glycoproteins (starting from 40 μg/ml). Bacterial
growth was measured at an optical density at A595 nm using
the Synergy HT multidetection microplate reader (Synergy
HT, Bio-Tek Instruments, Winooski, VT, USA). The MIC was
evaluated by recording the concentration of glycoproteins that
reduced bacterial growth by 99% in comparison to a control,
untreated culture, after 18 h incubation with shaking at 37◦C.
Statistical analysis and dose response curves were obtained using
K4 software provided by Synergy HT (Bio-Tek Instruments,
Winooski, VT, USA).
Strains Tested
Strains were fresh clinical isolates from the Clinical Microbiology
Laboratory, LHSC, London, ON, Canada. List of strains and their
antibiotics susceptibility is presented in Table 1. The isolates
tested per species were as follows: isolates of E. coli, three
isolates of MRSA, three isolates of P. aeruginosa, four isolates
of K. pneumoniae, four isolates of ESBL organisms including
Klebsiella oxytoca, one isolates of P. mirabilis, one isolates of
E. coli NDM-1, four isolates of VRE.
Control strains were E. coli ATCC 14948 and B. subtilis ATCC
6633.
Results
MALDI TOF of Honey Glycoproteins
Honey glycoproteins used in this study were isolated using
Concavalin A-agarose which binds high-mannose-type
N-glycans with high aﬃnity. The method allowed separation
of glycoproteins carrying such structures from a bulk of
honey proteins (Brudzynski and Sjaarda, 2015). The purity of
glycoprotein fractions was further analyzed using one- and
two-dimensional (2D) gel electrophoresis coupled with mass
spectrometry.
Two selected spots from the main 61 and 29 kDa bands
(Figure 1) were manually excised, subjected to in-gel tryptic
digestion and the peptide mass spectra were analyzed by MALDI
TOF. The generated peptide mass ﬁngerprints were search using
Mascot search engine against the NCBInr protein database. The
data obtained revealed that the 61 and 29 kDa of G208 protein
(Figure 1) presented a mixture of the major royal jelly proteins 1
and 2 precursors (Apis mellifera, accession number: gi 58585098-
MRJP1 and gi 58585108-MRJP2). The obtained scores were 281,
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TABLE 1 | Summary of MASCOT search results.
Protein band Accession Score Expect Peptide matches Mass kDa Name
61 kDa gi| 58585098 281 2.6e-21 41 49311 MRJP1
gi| 58585098 174 1.3e-10 22 49311 MRJP1
gi| 58585108 149 4.1e-08 19 51441 MRJP2
29 kDa gi| 58585108 325 8.6e+02 6 (2) 51441 MRJP2
gi| 58585098 202 1.7e+02 4(1) 49311 MRJP1
FIGURE 1 | 1D and 2D gel electrophoresis of glycoprotein G208. Lane
“i” – protein molecular weight standards, “ii” – buckwheat honey H208,
“iii” – glycoprotein G208, “iv” – glycoprotein G217, “v” – 2D gel electrophoresis
of G208. The arrows indicate location of 61 and 29 kDa bands. The line over
2D represents pH gradient from pH 3 (left) to pH 10 (right).
174, and 149 for 61 kDa band and the scores of 325 and 202
for the 29 kDa band where the individual ions scores > 55
indicate identity or extensive homology (p < 0.05). The protein
identiﬁcation data is detailed in Table 1.
While both proteins, MRJP1 and MRJP2 are highly
glycosylated (Kimura et al., 2006; Zhang et al., 2014), the
important structural diﬀerence between MRJP1 and MRJP2 is
the presence of antimicrobial peptides, Jelleins, in the C-terminal
of MRJP1 molecule.
Clinical Isolates
In order to investigate whether glps retain their antibacterial
activities against MDR bacteria including ESBL, we used
clinical isolates representing pathogens commonly involved in
nosocomial infections. At their arrival, isolates obtained the lab
numbers. The isolates included MRSA (n = 3), P. aeruginosa
(n = 4), K. pneumoniae (n = 2), VRE (n = 2), and ESBL
(n = 6; Table 1). After experiments were performed, the isolates
were identiﬁed to genus and species and their susceptibility to
antibiotics was conﬁrmed using an automated system (Vitek 2
R©
,
Biomérieux
R© ) by the Clinical Microbiology Laboratory, London
Health Science Centre, London, ON, Canada.
Table 2 indicates that microorganisms under study were
simultaneously resistant to a number of antibiotics representing
diﬀerent chemical classes: β-lactams (piperacillin-tazobactam,
ceftazidime, cefepime, ticarcillin-clavulanate), carbapenems
(imipenem, meropenem), aminoglycosides (gentamicin,
tobramycin, amikacin), and ﬂuoroquinolones (ciproﬂoxacin).
The isolates, therefore were classiﬁed as MDR pathogens.
In addition, strains of K. pneumonia 1 and 2 (lab#1 and
#19) and E. coli NDM 4 (lab #4) were recognized as possible
carbapenemase producers and K. pneumonia 2 (lab #19) and
ESBL-P. mirabilis showed resistance to colistin.
Susceptibility of Clinical Isolates to
Glycoproteins
In vitro evaluation of susceptibility of clinical isolates was
performed using a semi-quantitative radial well-diﬀusion and
broth microdilution assay. To compare the results of bacterial
susceptibility to honey glycoproteins in a quantitative manner,
the reference method has been designed that established the
relationship between ampicillin dilutions and zone of inhibition
(ZOI) in well-diﬀusion assay. As shown in Figure 2, the
series of twofold diluted honey glycoproteins and ampicillin
(1 mg/ml stock solutions) produced concentration-dependent
ZOIs with R2 = 0.99, for ampicillin and R2 = 0.96 and 0.95
for glps tested against E. coli and B. subtilis, respectively. MIC
values from well-diﬀusion assay against E. coli and B. subtilis
(1 × 106 CFU/ml) were <0.025 μg/well or <2.0 μg/ml for
ampicillin and<0.046 μg/well or 5.7 μg/ml for glps.
In a similar manner, each of isolates was tested for
susceptibility to glycoproteins by well-diﬀusion assay. The agar
plates were divided into three sections; the middle section was
used to spread plating of the standard E. coli (ATCC 14948)
sensitive to ampicillin while the right and left sections were
used to spread plate with the MDR isolates. The susceptibility of
isolates to two glycoproteins, G208 and G217, isolated from two
diﬀerent buckwheat honeys, was then evaluated and compared
to that of ampicillin-sensitive control. Both glycoproteins have
been shown to exhibit antibacterial activity againstK. pneumonia
1 and 2 (Table 2; lab number #1 and #19), P. aeruginosa 3 and
4 (lab number #34 and #35), E. coli NDM 4 (lab number #4),
and E. coli ESBL 2 (lab number #7). These results indicate that
MDR of isolates to antibiotics did not aﬀect antibacterial action
of glycoproteins (Figure 3 and Table 2).
All MRSA isolates were also highly sensitive to honey
glycoproteins (Figure 3). Moreover, in addition to G208,
glycoproteins G217, G125, and G207 isolated from diﬀerent
honeys, produced zones of inhibition of comparable diameters
(Figures 2 and 3), indicating that antibacterial activity of
glycoproteins resides in their common structure.
The serial two-fold dilution of glps showed a concentration-
dependent inhibition of growth of isolates in the radial diﬀusion
assay with susceptibility<0.1μg/well or<12.5μg/ml (Figure 4).
Diﬀerences in the mean of inhibition zone diameters between
bacterial species pointed out to some variation in the sensitivity
of individual strain to glps. Generally, glps were found less potent
in inhibition of growth of K. pneumonia and P. aeruginosa
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TABLE 2 | Antibiogram of clinical isolates used in this study.
Antimicrobial Escherichia coli Klebsiella
pneumoniae
(n = 2)
Pseudomonas
aeruginosa
Proteus
mirabilis
Methicillin
resistant
MRSA
VRE Enterococcus
faecium
1 2 3 4 1 2 3 1 2 3 4 1 1 2 3 1 2
E E E N E E
S S S D S S
B B B M B B
L L L L L
Amikacin S S S R R R S S S R R S
Amoxicillin-Clavulanate R R R R R R R R R R R S R R R
Ampicillin R R R R R R R R R R R R R R R R R
Aztreonam R R R S R R R I S I I S
Cefazolin R R R R R R R R R R R R R R R R R
Cefepime R R R R R R R R R R R S
Ceftazidime R R R R R R R R R R R S
Cefoxitin S I I R R R R R R R R S R R R R R
Ceftriaxone R R R R R R R R R R R
Cephalexin R R R R R R
Chloramphenicol S S S S R R S R R R R S S S S S S
Ciprofloxacin R R R R R R S R R R R S R R R R R
Clindamycin R R R R R
Colistin R S S S S R
Daptomycin S S S S S
Doxycyline S S S S S
Ertapenem S S S R R R R R R R R S
Erythromycin R R R R R
Fosfomycin S S S S R R R R
Fusidic acid R R
Gentamicin S S S R R R R R R R R R S S S R R
Imipenem S S S R R S S R R R R
Linezoid S S S S S
Meropenem S S S R R I S R R R R S
Moxofloxacin X X X
Mupirocin high level S S S
Nitrofurantoin S S S R R R R R R R R R S S S R R
Norfloxacin S R R R R R S R R R R S R R R R R
Oxacillin R R R
Penicillin G R R R R R
Piperacillin-tazobactam R S I R R R R R R S R S
Pristinamycin
Quinupristin-dalfopristin S S S S S
Rifampin S S S
Streptomycin-syn R R
Teicoplanin S S S R R
Tetracycline R S S R S S S R R R R R
Ticarcillin-Clavulanate I S R R R R R R R I R S
Tigecycline S S S S S S S R
Tobramycin R S R R R R R R R R R R
Trimethoprim R S R R R R S R R R R S S S S R R
Trimethoprim-Sulfamethoxazole R S R R R R S R R R R S S S S R R
Vancomycin S S S R R
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FIGURE 2 | Linear relationship between ampicillin and
glycoprotein concentrations and the diameter of the zone of
inhibition. (A) Amp against E. coli, (B) Amp against B. subtilis,
(C) relationship between the diameter of inhibition zone and
ampicillin concentration and (D). glp G208 against E. coli, (E) glp
G208 against B. subtilis, and (F) relationship between the diameter
of inhibition zone and glp concentrations. Columns represent means
and standard errors.
FIGURE 3 | Susceptibility of multidrug resistant clinical isolates to honey
glycoproteins. (A) Susceptibility of K. pneumonia (# 1and #19), P. aeruginosa
(#34, and #35), E. coli NDM (#4) and E. coli. ESBL (# 7) to G208 and G217.
Ampicillin-sensitive E. coli (ATCC14948) served as a control. (B) Susceptibility of
MRSA 1 (#5) and ampicillin-sensitive B. subtilis (ATCC 6633) to G208, G207,
G217 and G125 isolated from different honeys.
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FIGURE 4 | Concentration-dependent growth inhibition of multi-drug
resistant clinical isolates by honey glycoproteins in well-diffusion
assay.
compared to MRSA, VRE and E. coli NDM or standard,
antibiotic-sensitive bacteria, as judged by the size of ZOI they
produced at comparable concentrations (Figures 3 and 4).
In broth microdiltuion assay, glps showed considerable
antibacterial activity with MIC90 values ranging from 4.8 μg/ml
against B. subtilis to 14.4 μg/ml against K. pneumoniae, Klebsiella
spp. ESBL(lab number #9) and E. coli (Figure 5 and Table 3).
However, P. aeruginosa susceptibility diﬀered between individual
strains ranging from 5.7 to 33 μg/ml for P. aeruginosa (#6) and
P. aeruginosa #35, respectively.
Thus, honey glps showed activity against MDR clinical
isolates, irrespectively of the mechanism by which the resistance
was conferred.
Discussion
This study revealed that honey glycoproteins containing Major
Royal Jelly Proteins 1 and 2 possess a broad-spectrum of
antimicrobial activity against several clinical isolates of MDR
including ESBL producing gram-negative bacteria. Recently,
we have shown that glps are the membrane active molecules;
TABLE 3 | Minimum inhibitory concentrations (MIC).
Bacterial strain MIC90 (µg/ml) Antibiogram (Table 2)
MRSA (#5) 5.4 MRSA No. 1
MRSA (#6) 5.4 MRSA No.2
Klebsiella pneumonia (#1) 14.4 K. pneumonia No.1
K. pneumonia (#19) 14.4 K. pneumonia No.2
Pseudomonas aeruginosa (#34) 25.5 P. aeruginosa No.3
P. aeruginosa (#35) 33 P. aeruginosa No.4
P. aeruginosa (#6) 5.7 P. aeruginosa No.1
ESBL P. mirabilis (#2) 5.7 P. mirabilis No.1
ESBL Escherichia coli NDM (#4) 5.7 E. coli No.4
ESBL E. coli (#7) 23 E. coli No.1
ESBL E. coli (#8) 14.4 E. coli No.2
ESBL Klebsiella spp. (#9) 14.4 K. pneumonia No.3
ESBL E. coli (#10) 24.0 E. coli No.3
VRE (#17) 5.4 VRE No.1
VRE 5.7 VRE No.2
E. coli ATCC 15.8
B. subtilis ATCC 4.8
the treatment of bacterial cells with glps increased membrane
permeability for propidium iodide in 90% cells as indicated
by ﬂow cytometry, caused release of endotoxins from E. coli,
changed the cell shape of treated bacteria with formation
of ﬁlaments and spheroplasts, and ﬁnally evoked cell lysis
as evidenced by light and scanning electron microscopy
(Brudzynski and Sjaarda, 2014, 2015). Both MRJP1 and 2 are
highly glycosylated proteins with the high-mannose glycans
attached to the protein backbone ranging from 28 up to 178
glycosylation sites per molecule, respectively (Zhang et al., 2014).
Due to the presence of carbohydrate moiety, glps displayed lectin-
like activity, agglutinating both Gram-positive B. subtilis and
Gram-negative E. coli. Importantly, glps were able to eﬃciently
lyse bacteria. Bacterial killing by glps occurred very rapidly after
addition of glps to the bacterial cultures (Brudzynski and Sjaarda,
2015). The most important structural diﬀerence between the
MRJP1 and 2 is the presence of three antimicrobial peptides at
FIGURE 5 | Concentration-dependent growth inhibition of clinical isolates by honey glycoproteins evaluated using broth microdilution assay.
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the MRJP1 C-terminus (Fontana et al., 2004). As it was
impossible to separate MRJP1- from MRJP2- containing
glycoproteins in this study, we used their natural mixture to gain
a better understanding whether the antibacterial eﬀects of glps
would be retain against pathogens that develop several resistance
mechanisms.
An antibiogram of clinical isolates used in this study
indicates that in addition to being resistant to β-lactams, these
isolates were also resistant to carbapenems, ﬂuoroquinolones,
aminoglycosides and tetracyclines, therefore presenting MDR
phenotype. Among isolates tested, there were (ESBL)-producing
carbapenem-resistant K. pneumoniae (KPC), P. aeruginosa
(resistant to imipenem and cephalosporin, ceftazidime) and
E. coli NDM-1(New Delhi metallo-β-lactamase).
Despite ESBL and the coexistence of multiple resistance genes,
the isolates were susceptible to glps action. Both, well-diﬀusion
assay and broth microdilution assay provided evidence that
glps inhibited growth of MDR in a concentration-dependent
manner. The most sensitive isolates comprised MRSA and
VRE with MIC90 values of 5.4–5.7 μg/ml followed by two
strains of carbapenemase-producing K. pneumonia with MIC
14.4 μg/ml. All ESBL tested were inhibited by glps with MIC
ranging from 5.7 μg/ml against P. mirabilis and E. coli NDM
to 14.4 μg/ml against ESBL E. coli 14.4. However, highly
resistant strains of P. aeruginosa (#34 and#35) and one strain
of ESBL E. coli (#10) were the least sensitive to glps, with
MICs in the range of 33 and 24 μg/ml, respectively. Thus,
glps exhibited a consistent activity against the MDR isolates
irrespectively of the resistance mechanism. This indicates that
glps must exert their antibacterial action by yet a diﬀerent
mode of action than other classes of β-lactams. The fact that
glycoproteins G217, G125, and G207 isolated from diﬀerent
honey varieties also eﬃciently inhibited growth of MDR
points to the glps structure as the lead structure responsible
for the activity. Moreover, glps activity against MDR was
concentration-dependent as shown in both a semi-quantitative
well-diﬀusion and broth microdilution assays, providing further
evidence for the structure-activity relationship. Despite their
considerable size (61 kDa), glps exhibited antibacterial activity
at the microgram/ml concentrations, being in a range with
MICs of other classes of β-lactams. Our ongoing study on
the structure-activity relationship in which the antibacterial
activity of full-length glycoprotein G208 was compared to that
of synthetic Jelleins, (the antimicrobial peptides present in the
G208 molecule) showed that both compounds have a broad
spectrum of activity against Gram-positive and Gram-negative
bacteria and rapidly kill bacteria at very low concentrations
(paper submitted). Therefore, the bactericidal activity of glps
may result, at least in part, from the action of the antimicrobial
peptides, Jelleins.
These results show that glps structure is the lead structure
carrying glps antibacterial activity. Thus, honey MRJP-
containing glycoproteins possess suitable characteristics to be
considered a novel antibacterial drug candidate.
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